Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Jul;36(1):19–23. doi: 10.1111/j.1365-2125.1993.tb05886.x

A comparison of the effects of two putative 5-hydroxytryptamine renal prodrugs in normal man.

T C Li Kam Wa 1, S Freestone 1, R R Samson 1, N R Johnston 1, M R Lee 1
PMCID: PMC1364549  PMID: 7690583

Abstract

1. The effects of 1 h intravenous infusions of equimolar amounts of two putative 5-hydroxytryptamine (5-HT) renal prodrugs, 5-hydroxy-L-tryptophan (5-HTP, 10 micrograms kg-1 min-1) and gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP, 16.6 micrograms kg-1 min-1) were examined in five healthy male volunteers in a randomised, placebo-controlled, cross-over study. 2. Both compounds increased urinary excretion of 5-HT and there was greater extra-renal formation of 5-HT following 5-HTP administration than after glu-5-HTP. 3. Glu-5-HTP was significantly antinatriuretic. 5-HTP reduced mean urinary sodium excretion but this effect was not statistically significant. 4. 5-HTP, but not glu-5-HTP, significantly increased plasma aldosterone. There was no increase in plasma renin activity with either compound. 5. There were no significant changes in pulse rate or blood pressure. Two subjects complained of nausea at the end of 5-HTP infusion but none had any adverse reactions with glu-5-HTP. 6. The results of this study suggest that both prodrugs generate 5-HT in man and that glu-5-HTP is antinatriuretic. The glutamyl derivative may have greater renal specificity than 5-HTP and, as a result, causes less systemic side effects.

Full text

PDF
19

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Airaksinen M. M., Mattila K. Urinary and gastrointestinal excretion of metabolites of labelled 5-hydroxytryptamine and 5-hydroxytryptophan. Acta Pharmacol Toxicol (Copenh) 1967;25(4):473–482. doi: 10.1111/j.1600-0773.1967.tb00417.x. [DOI] [PubMed] [Google Scholar]
  2. DAVIDSON J., SJOERDSMA A., LOOMIS L. N., UDENFRIEND S. Studies with the serotonin precursor, 5-hydroxytryptophan, in experimental animals and man. J Clin Invest. 1957 Nov;36(11):1594–1599. doi: 10.1172/JCI103558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ding X. R., Stier C. T., Jr, Itskovitz H. D. Serotonin and 5-hydroxytryptophan on blood pressure and renal blood flow in anesthetized rats. Am J Med Sci. 1989 May;297(5):290–293. doi: 10.1097/00000441-198905000-00004. [DOI] [PubMed] [Google Scholar]
  4. Goldenberg H. Specific photometric determination of 5-hydroxyindoleacetic acid in urine. Clin Chem. 1973 Jan;19(1):38–44. [PubMed] [Google Scholar]
  5. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  6. Imura H., Nakai Y., Yoshimi T. Effect of 5-hydroxytryptophan (5-HTP) on growth hormone and ACTH release in man. J Clin Endocrinol Metab. 1973 Jan;36(1):204–206. doi: 10.1210/jcem-36-1-204. [DOI] [PubMed] [Google Scholar]
  7. Itskovitz H. D., Chen Y. H., Stier C. T., Jr Reciprocal renal effects of dopamine and 5-hydroxytryptamine formed within the rat kidney. Clin Sci (Lond) 1988 Nov;75(5):503–507. doi: 10.1042/cs0750503. [DOI] [PubMed] [Google Scholar]
  8. Jouve J., Martineau J., Mariotte N., Barthelemy C., Muh J. P., Lelord G. Determination of urinary serotonin using liquid chromatography with electrochemical detection. J Chromatogr. 1986 Jun 13;378(2):437–443. doi: 10.1016/s0378-4347(00)80739-2. [DOI] [PubMed] [Google Scholar]
  9. Maestri E., Camellini L., Rossi G., Rossi G. P., Dotti C., Marchesi M., Gnudi A. Serotonin regulation of aldosterone secretion. Horm Metab Res. 1988 Jul;20(7):457–459. doi: 10.1055/s-2007-1010859. [DOI] [PubMed] [Google Scholar]
  10. Magnussen I., Nielsen-Kudsk F. Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. Acta Pharmacol Toxicol (Copenh) 1979 Apr;44(4):308–314. doi: 10.1111/j.1600-0773.1979.tb02335.x. [DOI] [PubMed] [Google Scholar]
  11. Mashchak C. A., Kletzky O. A., Spencer C., Artal R. Transient effect of L-5-hydroxytryptophan on pituitary function in men and women. J Clin Endocrinol Metab. 1983 Jan;56(1):170–176. doi: 10.1210/jcem-56-1-170. [DOI] [PubMed] [Google Scholar]
  12. ORLOWSKI M., SZEWCZUK A. Colorimetric determination of gamma-glutamyl transpeptidase activity in human serum and tissues with synthetic substrates. Acta Biochim Pol. 1961;8:189–200. [PubMed] [Google Scholar]
  13. ROSENKRANTZ H. A direct influence of 5-hydroxytryptamine on the adrenal cortex. Endocrinology. 1959 Mar;64(3):355–362. doi: 10.1210/endo-64-3-355. [DOI] [PubMed] [Google Scholar]
  14. Shenker Y., Gross M. D., Grekin R. J. Central serotonergic stimulation of aldosterone secretion. J Clin Invest. 1985 Oct;76(4):1485–1490. doi: 10.1172/JCI112128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sole M. J., Madapallimattam A., Baines A. D. An active pathway for serotonin synthesis by renal proximal tubules. Kidney Int. 1986 Mar;29(3):689–694. doi: 10.1038/ki.1986.53. [DOI] [PubMed] [Google Scholar]
  16. Stier C. T., Jr, Itskovitz H. D. Formation of serotonin by rat kidneys in vivo. Proc Soc Exp Biol Med. 1985 Dec;180(3):550–557. doi: 10.3181/00379727-180-42216. [DOI] [PubMed] [Google Scholar]
  17. Stier C. T., Jr, McKendall G., Itskovitz H. D. Serotonin formation in nonblood-perfused rat kidneys. J Pharmacol Exp Ther. 1984 Jan;228(1):53–56. [PubMed] [Google Scholar]
  18. Wilk S., Mizoguchi H., Orlowski M. gamma-Glutamyl dopa: a kidney-specific dopamine precursor. J Pharmacol Exp Ther. 1978 Jul;206(1):227–232. [PubMed] [Google Scholar]
  19. Worth D. P., Harvey J. N., Brown J., Lee M. R. gamma-L-Glutamyl-L-dopa is a dopamine pro-drug, relatively specific for the kidney in normal subjects. Clin Sci (Lond) 1985 Aug;69(2):207–214. doi: 10.1042/cs0690207. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES